What changed
Every meaningful change to a compound entry, dated and sourced. Follow a compound to see its changes in My Research.
Saturday, October 24, 2026
New research reference added: Pentadeca arginate (PDA).
Removed a ClinicalTrials.gov record (NCT07487363) that its sponsor describes as an example, not a real study.
Source: TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD (NCT07487363)Removed a ClinicalTrials.gov record (NCT07505745) that its sponsor describes as an example, not a real study.
Source: MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (NCT07505745)Removed a ClinicalTrials.gov record (NCT07437547) that its sponsor describes as an example, not a real study.
Source: BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547)Removed a ClinicalTrials.gov record (NCT07437586) that its sponsor describes as an example, not a real study.
Source: Topical GHK-Cu Gel for Acute Skin Wound Healing (NCT07437586)WADA class corrected: tesofensine is listed under S6.B (specified stimulants), not S6.A.
Source: WADA 2026 Prohibited List (Tractatenblad 2026, 25)New research reference added: Apelin-13.
New research reference added: Thymulin.
New research reference added: MariTide (maridebart cafraglutide).
New research reference added: Ecnoglutide.
New research reference added: Matrixyl.
New research reference added: Argireline.
New research reference added: Adipotide.
New research reference added: Triptorelin.
New research reference added: Abaloparatide.
New research reference added: Leuprolide.
New research reference added: Thymosin beta-4.
New research reference added: Orforglipron.
New research reference added: hCG (human chorionic gonadotropin).
New research reference added: Octreotide.
New research reference added: Setmelanotide.
New research reference added: Teduglutide.
New research reference added: Larazotide.
New research reference added: Dulaglutide.
New research reference added: Exenatide.
New research reference added: Pramlintide.
New research reference added: Teriparatide.
New research reference added: Vasopressin.
Friday, October 23, 2026
Added week-by-week schedules from the FDA label (1 group, 1 arms).
Source: PITOCIN (oxytocin injection, USP) synthetic - prescribing informationAdded week-by-week schedules from registered trials (5 groups, 21 arms).
Source: A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (registry record and posted study protocol J1I-MC-GZBF)Added week-by-week schedules from registered trials (5 groups, 15 arms).
Source: A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight (registry results: participant flow group descriptions)Added week-by-week schedules from registered trials (1 group, 5 arms).
Source: Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity (registry results: participant flow group descriptions)Added week-by-week schedules from registered trials (3 groups, 7 arms).
Source: A Study of IBI362 in Participants With Obesity or Overweight (GLORY-1)Added week-by-week schedules from registered trials (1 group, 6 arms).
Source: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightAdded week-by-week schedules from registered trials (3 groups, 13 arms).
Source: Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled studyAdded week-by-week schedules from registered trials (1 group, 2 arms).
Source: Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b studyAdded week-by-week schedules from registered trials (1 group, 4 arms).
Source: Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE StudyAdded week-by-week schedules from registered trials (1 group, 3 arms).
Source: Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trialAdded week-by-week schedules from registered trials (1 group, 3 arms).
Source: Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisAdded week-by-week schedules from registered trials (2 groups, 2 arms).
Source: The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled TrialAdded week-by-week schedules from the FDA label (1 group, 1 arms).
Source: VYLEESI (bremelanotide injection), for subcutaneous use - prescribing informationAdded week-by-week schedules from the FDA label (1 group, 1 arms).
Source: SCENESSE (afamelanotide) implant, for subcutaneous use - prescribing informationAdded week-by-week schedules from the FDA label (1 group, 2 arms).
Source: EGRIFTA SV (tesamorelin) for injection, for subcutaneous use - prescribing informationAdded week-by-week schedules from the FDA label (2 groups, 4 arms).
Source: VICTOZA (liraglutide) injection, for subcutaneous use - prescribing informationAdded week-by-week schedules from the FDA label (2 groups, 5 arms).
Source: MOUNJARO (tirzepatide) injection, for subcutaneous use - prescribing informationAdded week-by-week schedules from the FDA label (4 groups, 11 arms).
Source: OZEMPIC (semaglutide) injection, for subcutaneous use - prescribing informationRe-cited the half-life to the population pharmacokinetic study that measured it (Alzheimer patients).
Source: PubMed 17324246Re-cited the half-life to the phase 1b study that measured it.
Source: PubMed 34430840Re-cited the half-life to the phase 1b study that measured it, and noted it was measured alongside semaglutide.
Source: PubMed 34798060Corrected the phase 2 amounts: no phase 2 trial gave 2 mg per day; the 2 mg amount was intravenous, in a pilot and a healthy-volunteer study.
Corrected the phase 2 treatment duration from 24–48 weeks to 36–48 weeks; 24 weeks was only the primary endpoint of the type 2 diabetes trial.
Source: PubMed 37385280Corrected which label each amount is cited to: tablet amounts now cite the Rybelsus/Ozempic tablets label and Wegovy amounts the Wegovy label.
The log began on Oct 23, 2026. Typo and layout fixes are not listed. Editorial policy.